FilingReader Intelligence
Haisco Pharmaceutical receives China clinical trial approval for HSK47977
August 12, 2025 at 05:13 PM UTC•By FilingReader AI
HSK47977 is an oral BCL6 PROTAC small molecule compound designed to treat Non-Hodgkin Lymphoma. This potential first-in-class product demonstrated strong anti-tumor activity in preclinical studies and synergy with BCL2 inhibitors.
Haisco Pharmaceutical Group also submitted an IND application to the FDA in July 2025 for simultaneous US development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime